Navigation Links
Area Health Care Providers Announce Plans to Integrate Services
Date:9/6/2007

PITTSBURGH, Sept. 6 /PRNewswire/ -- The sponsors of two of Pittsburgh's finest long term care providers have announced their intention to bring their organizations together within one health care system. Today, the Sisters of the Holy Spirit and the Vincentian Sisters of Charity announced that they will integrate Marian Manor Corporation, a 186-bed not for profit long term care facility operated by the Sisters of the Holy Spirit, into the Vincentian Collaborative System (VCS), a multi-institutional long term care provider operated by the Vincentian Sisters of Charity.

Sister Bridget Miller, Major Superior of the Sisters of the Holy Spirit of Pittsburgh, said, "After a long period of reflection on the future of health care delivery in this region and always within the context of offering the best care for our residents and their families, our congregation and our board decided that becoming an integral part of the Vincentian Collaborative System will best allow us to continue our mission and long heritage of quality care and dedicated service to the people of western Pennsylvania."

Sister Charlene Reebel, Major Superior of the Vincentian Sisters of Charity, said, "We welcome this opportunity to associate with a dedicated and caring organization such as Marian Manor. This integration means that we will all grow together in the future, enabling and strengthening our combined mission of service to the community in the areas of long term care and child development. Ten years ago we brought our three facilities together because we knew of the advantages that would accrue to each. Today we continue on this path so as to assure that mission-based and Catholic-based long term care and child development will continue to be available to the people of western Pennsylvania."

Marian Manor and Vincentian Collaborative System are now in the process of finalizing the formal agreements that will be presented to the Pennsylvania Department of Health and the st
'/>"/>

SOURCE Vincentian Collaborative System
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Startling Expose – Physicians Often Have No Regular Source Of Health Car
3. Debate Rages over firing of HIV infected health care workers
4. Want a Healthy brew? Have some Tea!
5. Patient’s perception of health status helps in better recover
6. Antioxidants protect health tissue in people undergoing radiation therapy.
7. Sexual abuse affect health for a lifetime
8. Smoking a greater risk than HIV? Yes say health experts!!!!
9. Healthcare sector is now a multi billion-dollar industry in India
10. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
11. How much can exercise improve health?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...ents freedom of movement, better quality of life ,... An automated artificial kidney that can be worn ...at the insulin pump is to diabetes patients. , ...orks better than conventional dialysis, according ...xperimental Nephrology . , "What,s really new a...
(Date:7/25/2008)...wswire-USNewswire/ -- Anthony Shih,M.D., M.P.H., ...e President,of Strategic Planning, after a two-yea...ation committed to improving U.S. health system pe...ram on Health Care Quality,Improvement and Efficie.../20080725/DC28791LOGO ), Board-certified in publ...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...sumers tips and encourages them to, ,Speak Up,(TM...uly 25 /PRNewswire-USNewswire/ -- The Pennsylvania... Patient Safety Day" which,is a national effort to...ate fully in their healthcare by asking questions ...ry or illness., "We understand the important role...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...again in UK when it has been hit by a virus the se...farm in Yorkshire//. The Centre for Environment F...sed a report that states that scientists are study...ausing viral Haemorrhagic Septicaemia (VHS). <...
...archers at the University of Wisconsin-Madison it ... have more to pay later. // Super-sized meals whi... calories which help a person to gain more weight....s, health care and more. An average upsized fast-...
...al Center, has said that awareness needs to be cre...anger. // It has stated that it is not the program...anger of falling TV sets. UT Southwestern pediatri...ency department cases involving children injured b...
...BA) have entered into a partnership to support a g... The campaign, 'Unite for Children, Unite against...S on children as well as impeding further spread o...ow that our sport, indeed all sports, has an enorm...
Other Medicine News:Health News:Adults Needs to be Educated About the Dangers of Elevated TVs 2
(Date:7/23/2008)... July 23 /- InCode BioPharmaceutics, ... announced preclinical test,results demonstrating ...,the treatment of the rare chronic blood disorder ...plete results will be presented at the XXII,Intern... September 28,2008., The only treatment currentl...
(Date:7/23/2008)...d on IND-Enabling Work with Protein Therapeutics t...lement System, CAMBRIDGE, Mass., July 23 /PRNewsw...it has initiated a corporate growth plan with the,...cutive officer and the,establishment of its headqu...oodruff Emlen, M.D., a co-founder of the company w...
(Date:7/22/2008)...acy results from a multi-center 293-patient Europe... Stock Exchange Symbol: CYT, MONTREAL, July 22 /P...c., the global leader in cryotherapy products to t...ults previously presented from three,European stud... Front(R),were published earlier today in the Jou...
(Date:7/22/2008)...under Therapeutics Development Initiative bring MJ... next deadline January 20,2009, NEW YORK, July 2...n to,speed delivery of transformative treatments a...Fox Foundation for Parkinson,s Research has awarde...search teams. The awards,were granted under MJFF,s...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 1Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4Field Museum Launches Shared Bike Program for Employees 15487 1Field Museum Launches Shared Bike Program for Employees 15487 2
...SINESS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (A...loping,oral spray formulations for a broad range o...o clinical studies comparing zolpidem,oral spray w...cokinetic (PK), pharmacodynamic (PD) and safety ob...as Ambien(R), a leading,drug for the treatment of ...
... III Study Results Presented At ASCO -- , CHICAGO ...ith,pegylated interferon alfa-2b in stage III mela...apse-free survival (RFS),according to the results...atients with stage III melanoma. Results of the Ph...r the Research and,Treatment of Cancer (EORTC) and...
Other Medicine Technology:NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: